

Section XXVIII  
Childhood Cancer by the International Classification of Childhood Cancer (ICCC)  
Incidence and Survival

The International Classification of Childhood Cancer (ICCC) was used to group histologic types and sites into meaningful categories. This classification was published by IARC (1). Since childhood cancer is rare in comparison to adult cancers, the rates presented in this section are per million children instead of per 100,000. The data presented are for invasive (malignant) tumors only.

- ◆ While the overall rate for all childhood (under age 15 years) cancers combined has increased about 0.7 percent per year between 1973 and 1996, the incidence has not increased during the more recent part of the time period, between 1985 to 1996, -0.1 percent per year.
- ◆ The incidence rates varied by ICCC group and age group. The highest incidence was leukemia for <5 and 5-9 year olds, CNS for 10-14 and lymphomas for 15-19 year olds.
- ◆ Changes in histologic diagnosis and changes to reporting requirements over time can affect the trends by specific histologic type. For example, primitive neuroectodermal tumor (PNET) is a relatively new diagnosis and showed an increase of 2.5 percent per year with a corresponding decrease of 2.0 percent per year in another CNS category, namely other gliomas. The overall CNS category showed little change, 0.2 percent per year between 1985 and 1996.
- ◆ It should be kept in mind that the estimated annual percent change (EAPC) and the percent change are relative percentages. In some cases, especially rare tumors, small absolute changes in the rates can translate to large changes in relative percentages. For example, hepatoblastoma increased 112 percent (probably due to more specificity as to the type of hepatic tumor over time) while the actual rate changed by less than 1 child per million children between 1973 and 1996.
- ◆ More detailed information by the ICCC groupings will be published in the monograph, *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, which will be available in 1999*. The monograph will contain information on cancer incidence, survival, risk factors and mortality. The monograph will also be released on the SEER Web page:  
<http://www-seer.ims.nci.nih.gov>

1) Kramarova E, Stiller CA. The international classification of childhood cancer. *Int. J. Cancer*: 68, 96:759-765. This classification was used with a slight modification: PNET cases outside of the brain/CNS were moved from III c to Ewing's sarcoma if bone and soft tissue sarcoma, otherwise.

Table XXVIII-1

## AGE-ADJUSTED AND AGE-SPECIFIC SEER CANCER INCIDENCE RATES, 1973-96§

By International Classification of Childhood Cancer (ICCC) Group and Subgroup and Age

All Races, Males and Females

| <u>ICCC Group and Subgroup</u>                       | <u>0-14</u> | <u>0-19</u> | <u>0-4</u> | <u>5-9</u> | <u>10-14</u> | <u>15-19</u> |
|------------------------------------------------------|-------------|-------------|------------|------------|--------------|--------------|
| All Groups Combined                                  | 134.3       | 149.1       | 190.9      | 105.4      | 115.2        | 194.1        |
| I Leukemia                                           | 40.4        | 36.0        | 67.5       | 34.2       | 23.8         | 22.9         |
| I(a) Lymphoid leukemia                               | 31.1        | 26.3        | 54.0       | 27.4       | 15.7         | 11.8         |
| Acute lymphoblastic leukemia (ALL)                   | 30.8        | 26.0        | 53.5       | 27.0       | 15.6         | 11.5         |
| Lymphoid excluding ALL                               | 0.3         | 0.3         | 0.5        | 0.4        | 0.2          | 0.4          |
| I(b) Acute non-lymphocytic leukemia                  | 6.2         | 6.5         | 8.5        | 4.5        | 5.8          | 7.6          |
| Acute myeloid leukemia (AML)                         | 4.5         | 4.9         | 5.6        | 3.7        | 4.4          | 6.2          |
| Acute non-lymphocytic excluding AML                  | 1.7         | 1.6         | 2.9        | 0.8        | 1.5          | 1.4          |
| I(c) Chronic myeloid leukemia                        | 0.9         | 1.2         | 1.0        | 0.7        | 1.1          | 2.1          |
| I(d) Other specified leukemias                       | 0.3         | 0.3         | 0.5        | 0.2        | 0.2          | 0.3          |
| I(e) Unspecified leukemias                           | 2.0         | 1.8         | 3.6        | 1.6        | 1.1          | 1.1          |
| II Lymphomas and reticuloendothelial neo.            | 15.4        | 24.1        | 7.1        | 13.0       | 24.4         | 50.5         |
| II(a) Hodgkin's disease                              | 6.4         | 13.8        | 0.6        | 4.1        | 13.5         | 36.2         |
| II(b) Non-Hodgkin's lymphomas                        | 5.4         | 6.9         | 3.6        | 5.3        | 7.0          | 11.4         |
| II(c) Burkitt's lymphoma                             | 2.1         | 1.9         | 1.5        | 2.5        | 2.3          | 1.1          |
| II(d) Miscellaneous lymphoreticular neo.             | 0.5         | 0.4         | 0.7        | 0.3        | 0.4          | 0.3          |
| II(e) Unspecified lymphomas                          | 0.9         | 1.1         | 0.6        | 0.9        | 1.3          | 1.5          |
| III CNS and misc intracranial and intraspinal neo.   | 28.1        | 25.9        | 32.0       | 29.4       | 23.7         | 19.0         |
| III(a) Ependymoma                                    | 2.5         | 2.1         | 5.2        | 1.4        | 1.5          | 0.9          |
| III(b) Astrocytoma                                   | 13.9        | 13.4        | 12.9       | 14.8       | 13.9         | 12.0         |
| III(c) Primitive neuroectodermal tumors              | 6.0         | 5.0         | 7.8        | 6.7        | 3.8          | 1.9          |
| III(d) Other gliomas                                 | 4.8         | 4.4         | 5.0        | 5.6        | 3.9          | 3.3          |
| III(e) Misc intracranial and intraspinal neo.        | 0.3         | 0.4         | 0.4        | 0.4        | 0.2          | 0.5          |
| III(f) Unspecified intracranial and intraspinal neo. | 0.6         | 0.6         | 0.8        | 0.6        | 0.4          | 0.5          |
| IV Sympathetic nervous system tumors                 | 10.1        | 7.9         | 29.0       | 3.2        | 1.2          | 1.1          |
| IV(a) Neuroblastoma and ganglioneuroblastoma         | 9.8         | 7.6         | 28.5       | 3.1        | 0.9          | 0.8          |
| IV(b) Other sympathetic nervous system tumors        | 0.3         | 0.3         | 0.6        | 0.1        | 0.3          | 0.3          |
| V Retinoblastoma                                     | 3.7         | 2.8         | 11.7       | 0.6        | 0.1          | 0.1          |
| VI Renal tumors                                      | 8.0         | 6.4         | 18.6       | 6.0        | 1.3          | 1.2          |
| VI(a) Wilms' tumor, rhabdoid and clear cell sarc.    | 7.8         | 6.0         | 18.5       | 5.8        | 0.9          | 0.4          |
| VI(b) Renal carcinoma                                | 0.2         | 0.4         | 0.2        | 0.2        | 0.4          | 0.8          |
| VI(c) Unspecified malignant renal tumors             | 0.0         | 0.0         | 0.0        | 0.0        | 0.0          | 0.0          |

Table XXVIII-1(cont'd)

## AGE-ADJUSTED AND AGE-SPECIFIC SEER CANCER INCIDENCE RATES, 1973-96§

By International Classification of Childhood Cancer (ICCC) Group and Subgroup and Age

All Races, Males and Females

| <u>ICCC Group and Subgroup</u>                             | <u>0-14</u> | <u>0-19</u> | <u>0-4</u> | <u>5-9</u> | <u>10-14</u> | <u>15-19</u> |
|------------------------------------------------------------|-------------|-------------|------------|------------|--------------|--------------|
| VII Hepatic tumors                                         | 1.7         | 1.5         | 4.3        | 0.6        | 0.7          | 0.8          |
| VII(a) Hepatoblastoma                                      | 1.3         | 1.0         | 4.0        | 0.2        | 0.1          | 0.1          |
| VII(b) Hepatic carcinoma                                   | 0.4         | 0.5         | 0.3        | 0.4        | 0.6          | 0.7          |
| VII(c) Unspecified malignant hepatic tumors                | 0.0         | 0.0         | 0.1        | 0.0        | 0.0          | 0.0          |
| VIII Malignant bone tumors                                 | 6.6         | 8.6         | 1.2        | 4.7        | 13.0         | 14.5         |
| VIII(a) Osteosarcoma                                       | 3.6         | 4.7         | 0.5        | 2.4        | 7.3          | 8.1          |
| VIII(b) Chondrosarcoma                                     | 0.3         | 0.5         | 0.1        | 0.1        | 0.7          | 1.3          |
| VIII(c) Ewing's sarcoma                                    | 2.5         | 3.0         | 0.6        | 2.1        | 4.5          | 4.6          |
| VIII(d) Other specified malignant bone tumors              | 0.2         | 0.3         | 0.1        | 0.1        | 0.4          | 0.5          |
| VIII(e) Unspecified malignant bone tumors                  | 0.1         | 0.1         | 0.1        | 0.1        | 0.1          | 0.1          |
| IX Soft-tissue sarcomas                                    | 9.5         | 10.8        | 10.2       | 8.4        | 9.9          | 14.7         |
| IX(a) Rhabdomyosarcoma and embryonal sarcoma               | 4.7         | 4.4         | 6.5        | 4.8        | 3.0          | 3.6          |
| IX(b) Fibrosarc., neurofibrosarc. and oth fibromatous neo. | 2.3         | 3.1         | 1.9        | 1.5        | 3.4          | 5.4          |
| IX(c) Kaposi's sarcoma                                     | 0.0         | 0.1         | 0.0        | 0.0        | 0.0          | 0.2          |
| IX(d) Other specified soft-tissue sarcomas                 | 1.6         | 2.2         | 1.1        | 1.3        | 2.3          | 3.7          |
| IX(e) Unspecified soft-tissue sarcomas                     | 0.9         | 1.1         | 0.7        | 0.7        | 1.3          | 1.7          |
| X Germ-cell, trophoblastic and other gonadal neo.          | 4.6         | 10.1        | 6.0        | 2.0        | 5.9          | 26.9         |
| X(a) Intracranial and intraspinal germ-cell tumors         | 0.9         | 1.1         | 0.4        | 0.8        | 1.5          | 1.8          |
| X(b) Other and unspecified non-gonadal germ-cell tumors    | 1.2         | 1.6         | 3.4        | 0.1        | 0.5          | 2.8          |
| X(c) Gonadal germ-cell tumors                              | 2.1         | 6.1         | 2.2        | 0.9        | 3.2          | 18.3         |
| X(d) Gonadal carcinomas                                    | 0.2         | 1.0         | 0.0        | 0.0        | 0.4          | 3.4          |
| X(e) Other and unspecified malignant gonadal tumors        | 0.1         | 0.3         | 0.1        | 0.1        | 0.2          | 0.7          |
| XI Carcinomas and other malignant epithelial neo.          | 5.3         | 14.1        | 1.7        | 2.9        | 10.6         | 40.9         |
| XI(a) Adrenocortical carcinoma                             | 0.2         | 0.2         | 0.5        | 0.2        | 0.1          | 0.2          |
| XI(b) Thyroid carcinoma                                    | 1.8         | 5.0         | 0.1        | 0.9        | 4.0          | 14.7         |
| XI(c) Nasopharyngeal carcinoma                             | 0.3         | 0.6         | 0.1        | 0.1        | 0.7          | 1.4          |
| XI(d) Malignant melanoma                                   | 1.5         | 4.5         | 0.7        | 0.9        | 2.6          | 13.7         |
| XI(e) Skin carcinoma                                       | 0.0         | 0.1         | 0.0        | 0.0        | 0.1          | 0.1          |
| XI(f) Other and unspecified carcinomas                     | 1.5         | 3.8         | 0.4        | 0.8        | 3.1          | 10.8         |
| XII Other and unspecified malignant neo.                   | 0.6         | 0.8         | 0.9        | 0.3        | 0.6          | 1.6          |
| XII(a) Other specified malignant tumors                    | 0.1         | 0.2         | 0.2        | 0.1        | 0.1          | 0.6          |
| XII(b) Other unspecified malignant tumors                  | 0.5         | 0.6         | 0.7        | 0.2        | 0.5          | 1.0          |
| Not classified by ICCC                                     | 0.3         | 0.3         | 0.9        | 0.1        | 0.1          | 0.1          |

§

SEER Program. Rates are per 1,000,000 and are age-adjusted to the 1970 U.S. standard.  
 Statistic could not be calculated.  
 Neoplasms are abbreviated as neo. Sarcomas are abbreviated as sarc.

Table XXVIII-2

AGE-ADJUSTED SEER CANCER INCIDENCE RATES, 1973-78, 1979-84, 1985-90, 1991-96§

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup and Year of Diagnosis

All Races, Males and Females, Ages 0-19

| <u>ICCC Group and Subgroup</u>                      | <u>1973-78</u> | <u>1979-84</u> | <u>1985-90</u> | <u>1991-96</u> |
|-----------------------------------------------------|----------------|----------------|----------------|----------------|
| All Groups Combined                                 | 138.3          | 144.3          | 155.9          | 157.8          |
| I Leukemia                                          | 34.9           | 34.8           | 37.5           | 36.9           |
| I(a) Lymphoid leukemia                              | 23.7           | 25.9           | 28.3           | 27.2           |
| Acute lymphoblastic leukemia (ALL)                  | 23.1           | 25.6           | 28.2           | 26.8           |
| I(b) Acute non-lymphocytic leukemia                 | 6.3            | 6.1            | 6.3            | 7.3            |
| Acute myeloid leukemia (AML)                        | 5.4            | 4.7            | 4.1            | 5.4            |
| II Lymphomas and reticuloendothelial neo.           | 23.5           | 24.6           | 24.7           | 23.7           |
| II(a) Hodgkin's disease                             | 14.0           | 14.4           | 14.1           | 12.8           |
| II(b,c,e) Non-Hodgkin's lymphomas                   | 8.9            | 9.7            | 10.2           | 10.7           |
| III CNS and misc intracranial and intraspinal neo.  | 22.6           | 22.5           | 28.9           | 29.0           |
| III(a) Ependymoma                                   | 1.9            | 1.5            | 2.6            | 2.4            |
| III(b) Astrocytoma                                  | 11.1           | 11.9           | 15.6           | 14.9           |
| III(c) Primitive neuroectodermal tumors             | 4.7            | 4.0            | 5.0            | 5.9            |
| III(d) Other gliomas                                | 3.8            | 4.2            | 4.6            | 5.1            |
| IV Sympathetic nervous system tumors                | 7.5            | 7.9            | 7.8            | 8.3            |
| IV(a) Neuroblastoma and ganglioneuroblastoma        | 7.4            | 7.5            | 7.4            | 7.9            |
| V Retinoblastoma                                    | 2.4            | 2.8            | 2.9            | 3.0            |
| VI Renal tumors                                     | 5.8            | 6.5            | 6.4            | 6.7            |
| VI(a) Wilms' tumor, rhabdoid and clear cell sarcoma | 5.4            | 6.3            | 6.0            | 6.2            |
| VII Hepatic tumors                                  | 1.4            | 1.4            | 1.4            | 1.8            |
| VII(a) Hepatoblastoma                               | 0.7            | 0.9            | 1.0            | 1.2            |
| VIII Malignant bone tumors                          | 7.5            | 9.0            | 9.0            | 9.0            |
| VIII(a) Osteosarcoma                                | 3.9            | 4.7            | 5.2            | 4.9            |
| VIII(c) Ewing's sarcoma                             | 2.5            | 3.6            | 3.0            | 3.1            |
| IX Soft-tissue sarcomas                             | 10.0           | 10.6           | 11.6           | 11.0           |
| IX(a) Rhabdomyosarcoma and embryonal sarcoma        | 4.1            | 4.1            | 4.9            | 4.6            |
| X Germ-cell, trophoblastic and other gonadal neo.   | 8.3            | 9.7            | 10.1           | 12.4           |
| X(a) Intracranial and intraspinal germ-cell tumors  | 0.5            | 1.1            | 1.1            | 1.9            |
| X(c) Gonadal germ-cell tumors                       | 5.4            | 6.1            | 6.3            | 6.9            |
| XI Carcinomas and other malignant epithelial neo.   | 13.3           | 13.5           | 14.6           | 15.1           |
| XI(b) Thyroid carcinoma                             | 4.8            | 4.7            | 5.3            | 5.2            |
| XI(d) Malignant melanoma                            | 3.6            | 4.0            | 5.3            | 5.2            |

§ SEER Program. Rates are per 1,000,000 and are age-adjusted to the 1970 U.S. standard.  
 - Statistic could not be calculated.  
 Neoplasms are abbreviated as neo.

Table XXVIII-3

## AGE-ADJUSTED SEER CANCER INCIDENCE TRENDS, 1973-96, 1973-84, 1985-96§

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup

All Races, Males and Females

| ICCC Group and Subgroup                           | Ages 0-14           |               |               |               | Ages 0-19           |               |               |               |
|---------------------------------------------------|---------------------|---------------|---------------|---------------|---------------------|---------------|---------------|---------------|
|                                                   | % Change<br>1973-96 | EAPC<br>73-96 | EAPC<br>73-84 | EAPC<br>85-96 | % Change<br>1973-96 | EAPC<br>73-96 | EAPC<br>73-84 | EAPC<br>85-96 |
| All Groups Combined                               | 7.5                 | 0.7★          | 0.5           | -0.1          | 12.1                | 0.8★          | 0.8★          | 0.1♦          |
| I Leukemia                                        | -0.5                | 0.4           | 0.0           | -0.5          | -1.6                | 0.4           | 0.1           | -0.2          |
| I(a) Lymphoid leukemia                            | 23.9                | 1.0★          | 2.0           | -0.4◇         | 22.5                | 1.0★          | 2.2★          | -0.3♦         |
| Acute lymphoblastic leukemia (ALL)                | 23.1                | 1.0★          | 2.1★          | -0.5♦         | 22.3                | 1.0★          | 2.3★          | -0.4♦         |
| I(b) Acute non-lymphocytic leukemia               | -9.9                | 0.3           | -2.0          | 0.2           | -8.8                | 0.5           | -2.1          | 1.1           |
| Acute myeloid leukemia (AML)                      | -26.4               | -1.0          | -5.4★         | 2.5♦          | -23.4               | -0.6          | -4.7★         | 3.4♦          |
| II Lymphomas and reticuloendothelial neo.         | -16.1               | -0.7★         | -0.5          | -1.5★         | 4.8                 | 0.1           | 1.2           | -0.8♦         |
| II(a) Hodgkin's disease                           | -29.7               | -1.4★         | -1.6          | -2.6          | -8.1                | -0.4          | 0.8           | -1.6          |
| II(b,c,e) Non-Hodgkin's lymphomas                 | 4.8                 | 0.2           | 1.0           | -0.4          | 34.1                | 1.1★          | 2.3★          | 0.4           |
| III CNS & misc intracranial & intraspinal neo.    | 31.9                | 1.8★          | 0.3           | 0.2           | 31.2                | 1.7★          | 0.4           | 0.1           |
| III(a) Ependymoma                                 | 61.8                | 2.1★          | -2.7          | 0.3           | 63.1                | 2.0★          | -2.7          | 0.0           |
| III(b) Astrocytoma                                | 68.9                | 2.5★          | 2.4           | 0.5           | 59.1                | 2.1★          | 2.3           | -0.1          |
| III(c) Primitive neuroectodermal tum.             | 13.3                | 1.5★          | -2.0          | 2.5           | 6.8                 | 1.6★          | -1.7          | 2.3           |
| III(d) Other gliomas                              | -8.9                | 1.0           | 1.4           | -2.0          | 15.0                | 1.4★          | 1.3           | -0.5          |
| IV Sympathetic nervous system tum.                | 26.4                | 0.6           | 1.4           | 0.9           | 24.4                | 0.5           | 1.2           | 0.8           |
| IV(a) Neuroblastoma and ganglioneuroblastoma      | 24.3                | 0.5           | 0.8           | 1.2           | 21.9                | 0.4           | 0.7           | 0.9           |
| V Retinoblastoma                                  | -19.7               | 0.5           | 0.5           | -1.1          | -19.7               | 0.5           | 0.5           | -1.1          |
| VI Renal tum.                                     | -1.6                | 0.5           | 1.9           | -0.3          | -3.1                | 0.5           | 1.9           | 0.0           |
| VI(a) Wilms' tum., rhabdoid & clear cell sarcoma  | -0.1                | 0.5           | 2.1           | -0.2          | -0.1                | 0.5           | 2.2           | 0.0           |
| VII Hepatic tum.                                  | 14.9                | 1.8           | 1.3           | 2.6           | 9.4                 | 2.0           | 2.3           | 1.0           |
| VII(a) Hepatoblastoma                             | 112.2               | 4.6★          | 5.5           | 3.3           | 92.0                | 4.4★          | 5.0           | 3.1           |
| VIII Malignant bone tum.                          | -9.6                | 0.3           | 1.9           | -1.9◇         | -0.8                | 0.7           | 2.0           | -1.0◇         |
| VIII(a) Osteosarcoma                              | -13.1               | 1.0           | 1.6           | -1.1          | 1.3                 | 1.1★          | 1.9           | -1.0          |
| VIII(c) Ewing's sarcoma                           | -28.1               | -0.5          | 4.5           | -3.4♦         | -19.8               | 0.2           | 4.5           | -2.0◇         |
| IX Soft-tissue sarcomas                           | 17.9                | 0.9           | 0.6           | 0.5           | 24.3                | 0.8           | 1.2           | -0.4          |
| IX(a) Rhabdomyosarcoma and embryonal sarcoma      | 38.0                | 1.2           | 0.5           | 0.9           | 24.4                | 1.0           | 0.1           | 0.5           |
| X Germ-cell, trophoblastic & other gonadal neo.   | 45.7                | 1.8★          | 2.7           | 5.6★          | 47.2                | 2.0★          | 2.0★          | 2.9★          |
| X(a) Intracranial and intraspinal germ-cell tum.  | 381.1               | -             | -             | -             | 548.0               | 7.7★          | 12.3          | 7.6           |
| X(c) Gonadal germ-cell tum.                       | -5.0                | -1.1          | -1.3          | -0.8          | 33.0                | 1.3★          | 2.1           | 1.1           |
| XI Carcinomas and other malignant epithelial neo. | 17.0                | 0.4           | -0.9          | 0.8           | 21.4                | 0.8★          | 0.1           | 0.6           |
| XI(b) Thyroid carcinoma                           | -29.7               | -0.5          | -1.2          | -2.1          | 22.5                | 0.6           | 0.8           | -0.3          |
| XI(d) Malignant melanoma                          | 121.6               | 2.8           | 0.2           | -0.3          | 93.2                | 2.3★          | 0.1           | 0.6           |

§ The EAPC is the Estimated Annual Percent Change over the time interval.

SEER Program.

★ The EAPC is significantly different from zero (p<.05).

♦ The EAPC for 1985-96 is significantly different from the EAPC for 1973-84 (p<.05).

◇ The EAPC for 1985-96 is significantly different from the EAPC for 1973-84 (p<.10).

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Tumors are abbreviated as tum.

Table XXVIII-4

## AGE-ADJUSTED SEER CANCER INCIDENCE TRENDS, 1973-96, 1973-84, 1985-96§

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup

All Races, Males

| Site                                              | Ages 0-14           |               |               |               | Ages 0-19           |               |               |               |
|---------------------------------------------------|---------------------|---------------|---------------|---------------|---------------------|---------------|---------------|---------------|
|                                                   | % Change<br>1973-96 | EAPC<br>73-96 | EAPC<br>73-84 | EAPC<br>85-96 | % Change<br>1973-96 | EAPC<br>73-96 | EAPC<br>73-84 | EAPC<br>85-96 |
| All Groups Combined                               | 6.9                 | 0.7★          | 0.0           | 0.0           | 10.8                | 0.8★          | 0.6           | 0.0           |
| I Leukemia                                        | -0.2                | 0.4           | -1.1          | -0.7          | -2.2                | 0.2           | -1.0          | -0.6          |
| I(a) Lymphoid leukemia                            | 19.8                | 0.9★          | 0.5           | -0.5          | 17.7                | 0.9★          | 1.1           | -0.5          |
| Acute lymphoblastic leukemia (ALL)                | 18.9                | 0.9★          | 0.7           | -0.7          | 17.7                | 0.9★          | 1.3           | -0.7          |
| I(b) Acute non-lymphocytic leukemia               | 17.3                | 0.6           | -2.5          | 0.4           | 7.5                 | 0.3           | -3.9★         | 1.5◆          |
| Acute myeloid leukemia (AML)                      | -14.0               | -0.9          | -7.3★         | 2.6◇          | -18.8               | -1.0          | -7.7★         | 3.4◆          |
| II Lymphomas and reticuloendothelial neo.         | -15.8               | -0.6          | 1.5           | -1.7◆         | 2.3                 | 0.0           | 1.9★          | -0.9◆         |
| II(a) Hodgkin's disease                           | -34.8               | -1.5          | -0.8          | -5.1★         | -10.9               | -0.7          | 1.1           | -2.8◇         |
| II(b,c,e) Non-Hodgkin's lymphomas                 | 2.6                 | 0.1           | 2.6           | 0.4           | 22.9                | 0.8           | 2.6★          | 0.7           |
| III CNS & misc intracranial & intraspinal neo.    | 38.0                | 2.0★          | 0.4           | 0.2           | 34.2                | 1.8★          | 0.7           | 0.1           |
| III(a) Ependymoma                                 | 82.5                | 2.9★          | -1.7          | 1.1           | 66.0                | 2.9★          | -1.8          | 0.5           |
| III(b) Astrocytoma                                | 97.1                | 2.8★          | 3.1           | 0.9           | 84.0                | 2.4★          | 3.7★          | -0.1◇         |
| III(c) Primitive neuroectodermal tum.             | 0.2                 | 1.7           | -1.9          | 2.8           | -11.2               | 1.6           | -2.0          | 2.3           |
| III(d) Other gliomas                              | -10.5               | 1.6           | 0.8           | -3.1          | 13.8                | 1.9★          | 0.3           | -0.8          |
| IV Sympathetic nervous system tum.                | 1.9                 | 0.5           | -0.3          | 2.3           | 3.1                 | 0.6           | -0.7          | 1.9           |
| IV(a) Neuroblastoma and ganglioneuroblastoma      | 0.3                 | 0.4           | -1.2          | 2.8           | -1.6                | 0.3           | -1.4          | 2.1           |
| V Retinoblastoma                                  | -36.1               | 0.7           | -0.5          | -0.2          | -36.1               | 0.8           | -0.5          | -0.2          |
| VI Renal tum.                                     | 16.9                | 1.5           | 2.8           | 0.0           | 20.1                | 1.4           | 2.7           | 0.4           |
| VI(a) Wilms' tum., rhabdoid & clear cell sarcoma  | 16.9                | 1.5           | 3.2           | 0.3           | 20.1                | 1.5★          | 3.6           | 0.5           |
| VII Hepatic tum.                                  | 4.7                 | 2.3           | -1.6          | 5.1           | -1.3                | 2.2           | -2.7          | 4.8           |
| VII(a) Hepatoblastoma                             | 68.1                | 3.5           | 1.2           | 7.9           | 68.1                | 3.2           | 0.5           | 7.5           |
| VIII Malignant bone tum.                          | -12.2               | 0.1           | 0.3           | -1.3          | 6.5                 | 1.0           | 2.0           | 0.1           |
| VIII(a) Osteosarcoma                              | -15.1               | 1.0           | 1.4           | -2.7          | 17.9                | 1.9★          | 3.1           | -0.9          |
| VIII(c) Ewing's sarcoma                           | -39.7               | -0.4          | 1.5           | -0.1          | -26.3               | -0.2          | 2.5           | 0.7           |
| IX Soft-tissue sarcomas                           | 26.4                | 1.0           | -0.3          | -0.3          | 22.9                | 0.8           | -0.3          | -1.2          |
| IX(a) Rhabdomyosarcoma and embryonal sarcoma      | 47.1                | 1.5           | -0.3          | -0.5          | 15.6                | 1.0           | -1.3          | -1.3          |
| X Germ-cell, trophoblastic & other gonadal neo.   | 68.7                | 1.4           | 0.2           | 7.7           | 63.8                | 2.1★          | 4.6★          | 3.1           |
| X(a) Intracranial and intraspinal germ-cell tum.  | 449.4               | -             | -             | -             | 694.3               | 7.8★          | 6.4           | 7.2★          |
| X(c) Gonadal germ-cell tum. (testis)              | -14.9               | -2.0          | -5.4          | -0.5          | 40.3                | 1.6★          | 5.0★          | 2.3           |
| XI Carcinomas and other malignant epithelial neo. | 6.2                 | 0.8           | -1.7          | -0.2          | 7.8                 | 0.7           | -0.2          | 0.2           |
| XI(b) Thyroid carcinoma                           | -77.5               | -             | -             | -             | -50.8               | -2.4          | 0.3           | -1.3          |
| XI(d) Malignant melanoma                          | 106.7               | 2.6           | -2.9          | -0.3          | 80.4                | 2.0           | -3.6          | -0.5          |

§ The EAPC is the Estimated Annual Percent Change over the time interval.

SEER Program.

★ The EAPC is significantly different from zero (p&lt;.05).

◆ The EAPC for 1985-96 is significantly different from the EAPC for 1973-84 (p&lt;.05).

◇ The EAPC for 1985-96 is significantly different from the EAPC for 1973-84 (p&lt;.10).

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Tumors are abbreviated as tum.

Table XXVIII-5

## AGE-ADJUSTED SEER CANCER INCIDENCE TRENDS, 1973-96, 1973-84, 1985-96§

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup

All Races, Females

| Site                                              | Ages 0-14           |               |               |               | Ages 0-19           |               |               |               |
|---------------------------------------------------|---------------------|---------------|---------------|---------------|---------------------|---------------|---------------|---------------|
|                                                   | % Change<br>1973-96 | EAPC<br>73-96 | EAPC<br>73-84 | EAPC<br>85-96 | % Change<br>1973-96 | EAPC<br>73-96 | EAPC<br>73-84 | EAPC<br>85-96 |
| All Groups Combined                               | 8.1                 | 0.6★          | 1.1           | -0.1          | 13.6                | 0.8★          | 1.0           | 0.1           |
| I Leukemia                                        | -1.0                | 0.5           | 1.4           | -0.3          | -1.1                | 0.6           | 1.5           | 0.2           |
| I(a) Lymphoid leukemia                            | 30.1                | 1.2★          | 3.7★          | -0.2◆         | 29.9                | 1.1★          | 3.6★          | 0.1◆          |
| Acute lymphoblastic leukemia (ALL)                | 29.3                | 1.2★          | 3.8★          | -0.3◆         | 29.2                | 1.1★          | 3.6★          | 0.0◆          |
| I(b) Acute non-lymphocytic leukemia               | -30.3               | -0.1          | -1.7          | 0.2           | -24.4               | 0.6           | -0.5          | 0.8           |
| Acute myeloid leukemia (AML)                      | -37.3               | -1.2          | -4.3          | 2.8◇          | -28.5               | -0.3          | -2.2          | 3.3◇          |
| II Lymphomas and reticuloendothelial neo.         | -16.9               | -0.8          | -4.5★         | -1.2          | 8.2                 | 0.3           | 0.0           | -0.7          |
| II(a) Hodgkin's disease                           | -24.1               | -1.2          | -3.2          | 1.0           | -4.9                | -0.1          | 0.3           | -0.3          |
| II(b,c,e) Non-Hodgkin's lymphomas                 | 9.6                 | 0.6           | -5.0          | -2.2          | 66.5                | 1.8★          | 0.9           | -0.4          |
| III CNS & misc intracranial & intraspinal neo.    | 24.6                | 1.5★          | 0.2           | 0.3           | 27.5                | 1.5★          | 0.1           | 0.1           |
| III(a) Ependymoma                                 | 43.5                | 1.7           | -1.8          | -0.5          | 59.7                | 1.6           | -1.6          | -0.6          |
| III(b) Astrocytoma                                | 41.4                | 2.2★          | 1.7           | 0.2           | 36.4                | 1.9★          | 0.8           | -0.1          |
| III(c) Primitive neuroectodermal tum.             | 39.7                | 1.5           | -2.4          | 2.2           | 45.3                | 1.6★          | -1.3          | 2.1           |
| III(d) Other gliomas                              | -6.8                | 0.6           | 2.6           | -0.3          | 16.5                | 1.2           | 2.7           | 0.4           |
| IV Sympathetic nervous system tum.                | 82.8                | 0.9           | 4.3           | -0.6          | 72.8                | 0.7           | 4.2           | -0.5          |
| IV(a) Neuroblastoma and ganglioneuroblastoma      | 79.7                | 0.8           | 4.0           | -0.5          | 76.3                | 0.7           | 4.1           | -0.3          |
| V Retinoblastoma                                  | 6.0                 | 0.7           | 2.0           | -1.7          | 6.0                 | 0.7           | 2.0           | -1.7          |
| VI Renal tum.                                     | -15.2               | -0.3          | 1.5           | -0.8          | -18.5               | -0.2          | 1.5           | -0.7          |
| VI(a) Wilms' tum., rhabdoid & clear cell sarcoma  | -12.8               | -0.4          | 1.5           | -0.9          | -14.6               | -0.3          | 1.6           | -0.8          |
| VII Hepatic tum.                                  | 48.5                | 1.8           | 7.5           | -1.3          | 41.1                | 2.1           | 10.0          | -2.8◆         |
| VII(a) Hepatoblastoma                             | 403.8               | -             | -             | -1.6          | 180.7               | -             | -             | -1.6          |
| VIII Malignant bone tum.                          | -5.6                | 0.5           | 3.6           | -2.9◇         | -13.4               | 0.1           | 1.7           | -3.0          |
| VIII(a) Osteosarcoma                              | -10.8               | 1.0           | 2.1           | 1.6           | -21.9               | 0.3           | 0.7           | -1.1          |
| VIII(c) Ewing's sarcoma                           | 13.2                | 0.4           | 10.2          | -7.2◆         | -3.8                | 1.1           | 6.3           | -5.0◇         |
| IX Soft-tissue sarcomas                           | 8.4                 | 0.9           | 1.7           | 1.6           | 25.9                | 0.7           | 2.7           | 0.7           |
| IX(a) Rhabdomyosarcoma and embryonal sarcoma      | 24.8                | 0.8           | 1.4           | 3.5           | 38.1                | 0.9           | 1.7           | 3.3           |
| X Germ-cell, trophoblastic & other gonadal neo.   | 28.9                | 1.9★          | 3.5           | 4.1           | 31.5                | 2.0★          | -0.4          | 2.8           |
| X(a) Intracranial and intraspinal germ-cell tum.  | 234.1               | -             | -             | -             | 234.1               | -             | -             | -             |
| X(c) Gonadal germ-cell tum. (ovary)               | 2.5                 | -0.6          | -1.6          | -1.4          | 22.4                | 1.1           | -2.2          | -0.5          |
| XI Carcinomas and other malignant epithelial neo. | 23.6                | 0.3           | 0.5           | 1.3           | 29.8                | 0.8           | 0.2           | 0.9           |
| XI(b) Thyroid carcinoma                           | -12.1               | 0.2           | -0.1          | -1.7          | 52.5                | 1.4★          | 1.1           | 0.1           |
| XI(d) Malignant melanoma                          | 134.1               | -             | -             | -2.5          | 104.8               | 2.6★          | 2.2           | 1.1           |

§ The EAPC is the Estimated Annual Percent Change over the time interval.

SEER Program.

★ The EAPC is significantly different from zero (p<.05).

◆ The EAPC for 1985-96 is significantly different from the EAPC for 1973-84 (p<.05).

◇ The EAPC for 1985-96 is significantly different from the EAPC for 1973-84 (p<.10).

- Statistic could not be calculated.

Neoplasms are abbreviated as neo. Tumors are abbreviated as tum.

Table XXVIII-6

5-YEAR RELATIVE SURVIVAL RATES, 1985-95<sup>b</sup>

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup and Sex and Age

| ICCC Group & Subgroup                             | Ages 0-19 by Sex  |                   |                   | Both Sexes by Age |                   |                   |                   |                   |
|---------------------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                                                   | Total             | Male              | Female            | 0-4               | 5-9               | 10-14             | 15-19             | 0-14              |
| All Groups Combined                               | 74.1              | 72.0              | 76.5              | 73.0              | 72.7              | 72.8              | 76.7              | 72.9              |
| I Leukemia                                        | 68.4              | 66.1              | 71.3              | 75.0              | 75.1              | 58.0              | 45.6              | 72.1              |
| I(a) Lymphoid leukemia                            | 76.8              | 74.6              | 79.8              | 82.7              | 80.6              | 66.7              | 50.8              | 79.7              |
| Acute lymphoblastic leukemia (ALL)                | 77.0              | 74.7              | 80.1              | 82.7              | 80.8              | 66.8              | 51.5              | 79.8              |
| I(b) Acute non-lymphocytic leukemia               | 40.1              | 35.4              | 44.5              | 36.2              | 46.6 <sup>†</sup> | 38.2 <sup>†</sup> | 41.9              | 39.3              |
| Acute myeloid leukemia (AML)                      | 41.6              | 35.4              | 47.1              | 36.2 <sup>†</sup> | 49.5 <sup>†</sup> | 41.8 <sup>†</sup> | 41.3 <sup>†</sup> | 41.8              |
| II Lymphomas & reticuloendothelial neo.           | 82.9              | 81.2              | 85.3              | 75.6              | 82.0              | 82.7              | 84.2              | 81.4              |
| II(a) Hodgkin's disease                           | 91.5              | 90.6              | 92.4              | -                 | 91.0              | 92.7              | 91.0              | 92.6              |
| II(b,c,e) Non-Hodgkin's lymphomas                 | 71.9              | 72.4              | 71.0              | 73.0              | 78.0              | 72.1              | 67.9              | 74.4              |
| III CNS and misc intracranial & intraspinal neo.  | 65.5              | 67.0              | 63.5              | 56.8              | 64.6              | 71.8              | 76.3              | 63.3              |
| III(a) Ependymoma                                 | 56.5              | 59.0              | 51.9 <sup>†</sup> | 40.9 <sup>†</sup> | 75.6 <sup>†</sup> | 78.3 <sup>†</sup> | -                 | 52.2              |
| III(b) Astrocytoma                                | 74.6              | 75.4              | 73.6              | 77.8              | 71.3              | 74.8              | 74.6              | 74.6              |
| III(c) Primitive neuroectodermal tumors           | 55.8              | 58.6              | 50.8              | 38.6              | 69.7              | 61.1 <sup>†</sup> | 74.8 <sup>†</sup> | 53.7              |
| III(d) Other gliomas                              | 57.4              | 61.9              | 52.2              | 56.0              | 42.5              | 68.1 <sup>†</sup> | 75.5 <sup>†</sup> | 53.4              |
| IV Sympathetic nervous system tumors              | 65.2              | 62.8              | 68.2              | 68.5              | 42.3 <sup>†</sup> | -                 | -                 | 66.0              |
| IV(a) Neuroblastoma and ganglioneuroblastoma      | 65.4              | 63.2              | 68.0              | 68.5              | 43.1 <sup>†</sup> | -                 | -                 | 66.3              |
| V Retinoblastoma                                  | 92.4              | 93.9              | 91.1              | 92.0              | -                 | -                 | -                 | 92.3              |
| VI Renal tumors                                   | 89.7              | 88.1              | 91.3              | 91.6              | 87.5              | -                 | -                 | 90.5              |
| VI(a) Wilms' tumor, rhabdoid & clear cell sarcoma | 90.4              | 88.7              | 92.2              | 91.7              | 87.1              | -                 | -                 | 90.6              |
| VII Hepatic tumors                                | 53.1              | 55.0 <sup>†</sup> | 50.8 <sup>†</sup> | 60.0 <sup>†</sup> | -                 | -                 | -                 | 58.4 <sup>†</sup> |
| VII(a) Hepatoblastoma                             | 61.1 <sup>†</sup> | 60.0 <sup>†</sup> | 61.9 <sup>†</sup> | 60.9 <sup>†</sup> | -                 | -                 | -                 | 61.8 <sup>†</sup> |
| VIII Malignant bone tumors                        | 63.8              | 59.3              | 70.0              | -                 | 66.4 <sup>†</sup> | 67.5              | 60.4              | 66.4              |
| VIII(a) Osteosarcoma                              | 63.5              | 59.1              | 69.8              | -                 | 59.9 <sup>†</sup> | 70.4              | 59.6              | 66.7              |
| VIII(c) Ewing's sarcoma                           | 58.6              | 51.2 <sup>†</sup> | 67.9 <sup>†</sup> | -                 | 69.8 <sup>†</sup> | 58.7 <sup>†</sup> | 54.7 <sup>†</sup> | 61.7              |
| IX Soft-tissue sarcomas                           | 70.3              | 71.7              | 68.5              | 78.0              | 74.4              | 70.4              | 61.8              | 74.4              |
| IX(a) Rhabdomyosarcoma & embryonal sarcoma        | 64.5              | 67.8              | 58.5              | 80.1              | 67.1 <sup>†</sup> | 47.3 <sup>†</sup> | 45.2 <sup>†</sup> | 69.0              |
| X Germ-cell, trophoblastic & other gonadal neo.   | 87.7              | 86.2              | 89.4              | 83.7              | 79.9 <sup>†</sup> | 84.1              | 89.8              | 83.3              |
| X(a) Intracranial & intraspinal germ-cell tumors  | 71.4 <sup>†</sup> | 70.5 <sup>†</sup> | 74.7 <sup>†</sup> | -                 | -                 | 84.4 <sup>†</sup> | 80.3 <sup>†</sup> | 65.1 <sup>†</sup> |
| X(c) Gonadal germ-cell tumors                     | 93.9              | 94.6              | 92.7              | 100.0             | -                 | 93.5              | 93.0              | 97.0              |
| XI Carcinomas & other malignant epithelial neo.   | 89.0              | 81.9              | 92.7              | 74.4 <sup>†</sup> | 94.5              | 91.1              | 88.7              | 89.6              |
| XI(b) Thyroid carcinoma                           | 98.7              | 95.9              | 99.3              | -                 | -                 | 98.1              | 98.8              | 98.4              |
| XI(d) Malignant melanoma                          | 91.2              | 88.2              | 93.4              | -                 | -                 | 87.7 <sup>†</sup> | 92.2              | 87.9              |

<sup>b</sup> Rates are from the SEER Program. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients through 1996.

<sup>†</sup> The standard error of the survival rate is between 5 and 10 percentage points.


- Statistic could not be calculated.

Neoplasms are abbreviated as neo.

Survival rates are relative rates expressed as percents.




# SEER Incidence and U.S. Mortality All Childhood Cancers, Under 20 Years of Age Both Sexes, All Races, 1973-1996




Age-adjusted to 1970 Standard

# Childhood Cancer SEER Incidence Rates 1973-1996, by ICCC Group Under 20 Years of Age, Both Sexes, All Races



Age-adjusted to 1970 Standard

# Childhood Cancer SEER Incidence Rates 1990-1996 by ICCG Group and Race/Ethnicity Both Sexes, Under 20 Years of Age



^^ Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Native Alaskans.

\*\*\* Asian/Pacific Islander populations are unadjusted Census Bureau estimates.

Data Source: SEER 11

Age-adjusted to 1970 Standard